The Business Research Company’s 2026 market reports feature enhanced tools like market attractiveness analysis, TAM assessment, and company scoring matrices, along with interactive dashboards, deeper supply chain insights, and startup coverage strengthening the depth, usability, and strategic value of insights.
What Is The Estimated Market Size Of The Neurological Biomarkers Market In 2026, And How Will Its Value Evolve By 2030?
Recent years have seen a swift expansion in the size of the neurological biomarkers market. This market is set to expand from $11.92 billion in 2025 to $13.52 billion in 2026, at a compound annual growth rate (CAGR) of 13.4%. The historical increase can be ascribed to the rising prevalence of neurological disorders, the early development of protein biomarkers, increased utilization of imaging biomarkers, the growing adoption of DNA biomarkers, and the initial integration of biomarkers within clinical trials.
The neurological biomarkers market is anticipated to experience significant expansion in the upcoming years. This market is projected to reach $22.82 billion by 2030, exhibiting a compound annual growth rate (CAGR) of 14.0%. This projected growth is driven by factors such as the expanding application of personalized medicine based on biomarkers, increasing demand for metabolomics biomarkers, higher investments in CNS drug development, the emergence of advanced diagnostic platforms, and the increasing utilization of biomarkers for disease monitoring. Key trends anticipated during this period encompass the increasing integration of biomarkers in early neurological diagnosis, wider adoption of proteomic and genomic biomarkers, the broadening use of imaging biomarkers for CNS disorder assessment, an escalating demand for biomarkers within drug development pipelines, and a heightened clinical emphasis on testing biomarkers for neurodegenerative diseases.
Access Your Free Sample Report For In-Depth Market Analysis:
https://www.thebusinessresearchcompany.com/sample.aspx?id=12677&type=smp
Which Important Drivers Are Guiding The Neurological Biomarkers Market Growth?
The rising occurrence of neurological diseases is anticipated to boost the expansion of the neurological biomarker market in the future. These illnesses impact the brain, spinal cord, and the entire nervous system throughout the body. Parkinson’s disease, for instance, is a neurodegenerative condition that targets the neurological system and nerve-controlled regions of the body. Neurological biomarkers facilitate the early detection of Parkinson’s disease through pathological, biochemical, and genetic analyses. A notable example is data from October 2023, where the World Federation of Neurology, a UK-based charity, reported that neurological disorders, indicating a rapidly increasing global health burden, are presently the second-leading cause of death and the primary cause of disability worldwide. In 2023, over 40 percent of the global population was affected, and the number of people living with brain disease is expected to nearly double by 2050. Consequently, the expanding incidence of neurological diseases is propelling the growth of the neurological biomarker market.
Which Segments Define The Neurological Biomarkers Market Segment Structure?
The neurological biomarkers market covered in this report is segmented –
1) By Product: Proteomics Biomarker, Genomics Biomarker, Metabolomics Biomarker, Imaging Biomarker, Other Products
2) By Application: Alzheimer’s Disease, Parkinson’s Disease, Huntington’s Disease, Schizophrenia, Depression, Multiple Sclerosis, Spinal Muscular Atrophy
3) By End-User: Hospital Laboratories, Clinical Diagnostic Centers, Research Organizations, Other End-Users
Subsegments:
1) By Proteomics Biomarker: Protein Biomarkers, Antibody Biomarkers
2) By Genomics Biomarker: DNA Biomarkers, RNA Biomarkers
3) By Metabolomics Biomarker: Metabolite Biomarkers, Lipid Biomarkers
4) By Imaging Biomarker: MRI Biomarkers, PET Scan Biomarkers
5) By Other Products: Neuroinflammatory Biomarkers, Neurotransmitter Biomarkers
What Trends Are Influencing The Evolution Of The Neurological Biomarkers Market?
Leading companies in the neurological biomarkers market are developing new offerings, such as advanced biomarker blood tests, to gain a competitive edge. These biomarker blood tests involve analyzing specific molecules or indicators in the blood to provide information about a biological condition, disease, or physiological process. For example, in July 2023, Quanterix Corporation, a US-based firm specializing in the development and commercialization of ultra-sensitive digital immunoassay platforms, introduced the LucentAD biomarker blood test. The LucentAD test is designed to assist medical professionals in evaluating patients who display cognitive symptoms consistent with early indications of Alzheimer’s disease. This test quantifies levels of p-Tau 181, which has been identified as a biomarker for the pathophysiology of Alzheimer’s disease (AD). When an adult is undergoing testing for AD 1 and exhibits cognitive impairment, the LucentAD test findings are intended to be used as a diagnostic tool. The test is not meant to be a standalone screening or diagnostic assay and must be used in conjunction with other diagnostic tools.
Who Are The Established Players Within The Neurological Biomarkers Market?
Major companies operating in the neurological biomarkers market are Pfizer Inc., F. Hoffmann-La Roche AG, Merck & Co. Inc., Novartis AG, Thermos Fisher Scientific Inc., AstraZeneca Plc, Abbott Laboratories, Boehringer Ingelheim International GmbH, Becton Dickinson and Company, Agilent Technologies Inc., Grifols S.A., Eisai Co. Ltd., PerkinElmer Inc., Illumina Inc., Shimadzu Corporation, Waters Corporation, Bio-Rad Laboratories Inc., Mallinckrodt Plc, Qiagen N.V., Luminex Corporation, Siemens Healthineers, Olink Proteomics, Meso Scale Diagnostics, Quanterix Corp., Fujirebio, Cisbio Bioassays SAS, NeuroVision Imaging, Proteome Sciences Plc, Acumen Pharmaceuticals.
Get The Full Neurological Biomarkers Market Report:
https://www.thebusinessresearchcompany.com/report/neurological-biomarkers-global-market-report
Which Region Leads The Neurological Biomarkers Market In Terms Of Market Share?
North America was the largest region in the neurological biomarkers market in 2025. The regions covered in the neurological biomarkers market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.
Request A Customized Neurological Biomarkers Market Report For Competitive Insights:
https://www.thebusinessresearchcompany.com/report/neurological-biomarkers-global-market-report
Browse Through More Reports Similar to the Global Neurological Biomarkers Market 2026, By The Business Research Company
Genomics Market Report 2026
https://www.thebusinessresearchcompany.com/report/genomics-global-market-report
Neurological Biomarkers Market Report
https://www.thebusinessresearchcompany.com/report/neurological-biomarkers-global-market-report
Neuroscience Market Report
https://www.thebusinessresearchcompany.com/report/neuroscience-global-market-report
Get in touch with us:
The Business Research Company: https://www.thebusinessresearchcompany.com/
Americas +1 310-496-7795
Asia +44 7882 955267 & +91 8897263534
Europe +44 7882 955267
Email us at info@tbrc.info
Follow us on:
LinkedIn: https://in.linkedin.com/company/the-business-research-company
YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ
Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model